Full-Time

Senior Director

Clinical Compliance and Training

Posted on 9/17/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$261k - $319kAnnually

Senior

San Bruno, CA, USA

Requires onsite presence in South San Francisco; remote work not supported.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • ICH/GCP expert with a strong understanding of FDA and EMEA regulations related to clinical development
  • BA/BS in science-related field. 15+ years’ work experience including Clinical Operations and Quality Assurance
  • Highly experienced as a Trainer, Training Facilitator or similar role
  • Advanced experience coordinating training events in a corporate setting
  • Adequate knowledge of learning management systems and web delivery tools
  • Excellent communication skills (verbal and written), including interpersonal skills with demonstrated successful team participation
  • Experience in Root Cause Analysis methodologies and CAPA management
  • Experience in supporting clinical trial GCP compliance/quality management activities and initiative
  • Strong understanding of drug development and clinical trial execution including cross functional areas involved in clinical trials
  • Experience in supporting GCP inspection readiness activities and participated in regulatory authority inspections
  • Strong leadership abilities to inspire and motivate others to achieve results
  • Strong analytical and problem-solving skills, with the ability to collect and analyze data to inform talent management decisions
  • Exceptional organizational and project management skills, with the ability to manage multiple priorities and meet deadlines
  • Ability to adapt to a fast-paced and changing environment and drive change within the organization
Responsibilities
  • Strategically lead the Clinical Compliance & Training function to deliver knowledge, training, oversight, guidance and support, to promote and maintain GCP compliance for the operation and execution of Cytokinetics clinical development programs.
  • Be the SME for Development Operations personnel for issues relating to GCP, non-compliance surveillance, Quality Events, audit/inspection responses and process optimization
  • Track quality issues, deviations, and corrective actions ensuring effectiveness and delivery
  • Partner with Development Operations personnel in Root Cause analyses and advises on content of CAPAs and audit/inspection responses
  • Drive the design, development and execution of development and training programs to support process quality and inspection readiness
  • Evaluate business unit needs to design, develop and implement annual training plans for Clinical Development departments
  • Partner with Clinical Operations, Quality Assurance, Data Management, Biostatistics, Statistical Programming, Medical Science, Drug Safety and Pharmacovigilance, and Corporate Compliance to manage study-specific training and ensure adherence to GCP compliance execution
  • Partner with Clinical Quality Assurance on remediation of quality issues related to clinical study conduct. Act as a liaison with Clinical Quality Assurance to ensure coordination and communication of quality driven initiatives, to ensure alignment on compliance decisions and recommended actions implementation

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a range of drugs in clinical trials, including omecamtiv mecarbil and reldesemtiv, aimed at treating conditions like heart failure, ALS, and HCM. What sets Cytokinetics apart from competitors is its dedicated focus on muscle-related diseases and its extensive pipeline of potential treatments. The goal of Cytokinetics is to bring effective therapies to market that address the unmet medical needs of patients suffering from debilitating muscle conditions.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma for R&D and commercial launch.
  • Positive Phase III results for aficamten in treating obstructive hypertrophic cardiomyopathy.
  • Increased investment interest, with $1.73M from Intech and $1.88M from Bridger Management.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos in hypertrophic cardiomyopathy market.
  • Reliance on successful clinical trial outcomes for financial stability.
  • Need for substantial capital, indicated by recent public offering and external funding.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets niche markets like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics has a robust pipeline including omecamtiv mecarbil and aficamten.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE